Aberrant expression of the MET receptor, defined by immunohistochemical (IHC) staining and manifested through amplification, mutation, alternative exon splicing, and abnormal protein metabolism, has led to the development of small-molecule kinase inhibitors (SMKIs) and conventional therapeutic monoclonal antibodies (TmAbs) for targeted cancer therapy. SMKIs have been approved for clinical application. However, conventional anti-MET TmAbs, although under clinical trials for 10 years, have made little progress, with various setbacks, raising uncertainty about their usefulness. In this review, we discuss the relevance of MET overexpression and the latest development of bispecific antibodies, antibody–drug conjugates (ADCs), and their combined products for clinical development. Evidence from preclinical and clinical studies highlights the potential of these novel MET-targeted biotherapeutics for cancer therapy in the future.

MET 受体的异常表达，由免疫组织化学 (IHC) 染色定义，并通过扩增、突变、选择性外显子剪接和异常蛋白质代谢表现出来，导致了小分子激酶抑制剂 (SMKI) 和常规治疗性单克隆抗体的发展。 TmAb) 用于靶向癌症治疗。SMKI 已被批准用于临床。然而，传统的抗 MET TmAbs 尽管已经进行了 10 年的临床试验，但进展甚微，并存在各种挫折，增加了对其有用性的不确定性。在这篇综述中，我们讨论了 MET 过表达的相关性以及双特异性抗体、抗体-药物偶联物 (ADC) 及其用于临床开发的组合产品的最新发展。